Background Many systemic therapies for advanced prostate cancer work by disrupting
androgen receptor signaling. Androgen indifferent prostate cancer (AIPC) variants, including …

Metastatic castration-resistant prostate cancer (CRPC) is associated with substantial clinical,
pathologic, and molecular heterogeneity. Most tumors remain driven by androgen receptor …

Simple Summary Approximately 1 in 8 men will be diagnosed with prostate cancer (PCa) at
some point in their lifetime. Five-year survival rate for patients with local or regionally spread …

Prostate cancer (PCa) is the most widely diagnosed male cancer in the Western World and
while low-and intermediate-risk PCa patients have a variety of treatment options, metastatic …

Simple Summary Early-stage and castration-sensitive prostate cancer (PCa) growth is solely
mediated by androgen signaling pathways. AR signaling inhibitors (ARSIs) have …

While there are myriad mechanisms of primary and acquired resistance to conventional and
next-generation hormonal therapies in prostate cancer, the potential role of androgen …

Abstract Background Approximately 10–30% of men with mCRPC will test positive for AR-V7
using one of two analytically and clinically validated circulating tumor cell (CTC)-based …

Recent genomic analyses of metastatic prostate cancer have provided important insight into
adaptive changes in androgen receptor (AR) signaling that underpin resistance to androgen …

Hormonal therapies including androgen deprivation therapy and androgen receptor (AR)
pathway inhibitors such as abiraterone and enzalutamide have been widely used to treat …

Context Although a number of studies have demonstrated the importance of constitutively
active androgen receptor variants (AR-Vs) in prostate cancer, questions still remain about …